Technology evaluation: mepolizumab, GlaxoSmithKline
Gnanakumaran, G.; Babu, K.S.
Current Opinion in Molecular Therapeutics 5(3): 321-325
2003
ISSN/ISBN: 1464-8431 PMID: 12870444 Document Number: 557085
GlaxoSmithKline (formerly SmithKline Beecham) is developing mepolizumab (SB-240563), a monoclonal antibody directed against IL-5, as a potential treatment for asthma and atopic dermatitis. Phase II trials in asthma were underway by April 1998 and by March 2002, phase II trials had also been initiated in atopic dermatitis.